A critical risk to the continued success of antifungal chemotherapy is the acquisition of resistance; a risk exacerbated by the few classes of effective antifungal drugs. Predictably, as the use of these drugs increases in the clinic, more resistant organisms can be isolated from patients. A particularly problematic form of drug resistance that routinely emerges in the major fungal pathogens is...

Azole compounds are the primary therapy for patients with diseases caused by Aspergillus fumigatus. However, prolonged treatment may cause resistance to develop, which is associated with treatment failure. The azole target cyp51A is a hotspot for mutations that confer phenotypic resistance, but in an increasing number of resistant isolates the underlying mechanism remains unknown. Here, we repo...

Abstract Poster session 1, September 21, 2022, 12:30 PM - 1:30 Objectives In Italy, a prevalence of 16.9% resistance to clinical azoles was observed among Aspergillus fumigatus isolates from an agricultural environment. This spread azole-resistance is attributed the widespread use 14a-demethylase inhibitors (DMIs). The aims present study were investigate: DMIs in Italian A. strains and environm...

The Antifungal Susceptibility Testing method of the European Committee on Antimicrobial (EUCAST-AFST) is a reference technique for determination Minimum Inhibitory Concentration (MIC) antifungals Aspergillus fumigatus. However, it time-consuming and requires expertise. Micronaut-AM (M-AM) fast, simple, time-saving, ready-to-use new colorimetric using an indicator (resazurin) to facilitate visua...

We report the first isolation of a voriconazole-resistant Aspergillus fumigatus strain harbouring the azole resistance mechanism TR46/Y121F/T289A, recovered from an azole-naive patient in Spain with chronic obstructive pulmonary disease. This new finding in Spain suggests the spread of this resistance mechanism and reinforces the need for antifungal susceptibility surveillance.